Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample

被引:109
作者
Allen, Richard P. [1 ]
Ondo, William G. [2 ]
Ball, Eric [3 ]
Calloway, Michael O. [4 ]
Manjunath, Ranjani [4 ]
Higbie, Rachel L. [5 ]
Lee, Mechele R. [5 ]
Nisbet, Paul A. [5 ]
机构
[1] Johns Hopkins Univ, Baltimore, MD 21218 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Walla Walla Clin, Walla Walla, WA USA
[4] GlaxoSmithKline, Res Triangle Pk, NC USA
[5] Harris Interact, Rochester, NY USA
关键词
RLS; Restless legs syndrome; Dopamine; Dopamine agonists; Levodopa; Augmentation; RLS augmentation; Community RLS patients; LONG-TERM TREATMENT; CONTROLLED-TRIAL; PRAMIPEXOLE; MULTICENTER; MANAGEMENT; EFFICACY; FERRITIN;
D O I
10.1016/j.sleep.2011.03.003
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Assess the rate of augmentation as it occurs during standard long-term dopaminergic treatment of RLS, potential risk factors or predictors of augmentation, the relationship between treatment duration and augmentation, and the clinical impact of augmentation on subjects' health outcomes. Methods: Two hundred sixty-six patients with dopamine-treated RLS completed a one-time online survey. All subjects were recruited by their PCP/neurologist and were 18 or older. Augmentation was assessed using NIH guidelines and an augmentation classification system was developed through this research. Results: Overall, 20% of the patients were classified as having definitive or highly suggestive clinical indications of augmentation. Five factors were considered likely to reflect increased risk of developing augmentation, including more frequent RLS symptoms pre-treatment, greater discomfort with RLS symptoms before treatment, and longer treatment duration. RLS augmentation occurred at a rate of about 8% each year for at least the first 8 years of dopamine treatment. Subjects reporting definite or highly suggestive clinical indicators of augmentation had an average IRLS score of 23.6, indicating generally inadequate treatment with generally poor clinical outcomes. Only 25% of the patients reported no indications of augmentation and they were the only group to show on average a low (<15) IRLS score and good clinical outcomes. Conclusions: As currently used, long term dopaminergic treatment for an average +/- SD of 2.7 +/- 2.4 years produced significant augmentation problems in at least 20% of the patients and only 25% of the patients were totally free of this problem. It is important for physicians to carefully screen patients for changes in RLS symptoms for as long as they are on dopamine agents, with particular attention paid to those patients who present with the most severe RLS symptoms prior to treatment initiation. Given the marked increase in suffering with augmentation, a method for early detection and intervention would be an important contribution to the effective management and treatment of RLS. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:431 / 439
页数:9
相关论文
共 22 条
[1]   Evaluating the quality of life of patients with restless legs syndrome [J].
Abetz, L ;
Allen, R ;
Follet, A ;
Washburn, T ;
Earley, C ;
Kirsch, J ;
Knight, H .
CLINICAL THERAPEUTICS, 2004, 26 (06) :925-935
[2]   Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology - A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health [J].
Allen, RP ;
Picchietti, D ;
Hening, WA ;
Trenkwalder, C ;
Walters, AS ;
Montplaisi, J .
SLEEP MEDICINE, 2003, 4 (02) :101-119
[3]   Augmentation of the restless legs syndrome with carbidopa/levodopa [J].
Allen, RP ;
Earley, CJ .
SLEEP, 1996, 19 (03) :205-213
[4]   Restless legs syndrome augmentation and pramipexole treatment [J].
Ferini-Strambi, L. .
SLEEP MEDICINE, 2002, 3 :S23-S25
[5]   The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: Association with ferritin levels [J].
Frauscher, Birgit ;
Gschliesser, Viola ;
Brandauer, Elisabeth ;
El-Demerdash, Essam ;
Kaneider, Matthias ;
Ruecker, Lukas ;
Poewe, Werner ;
Hoegl, Birgit .
SLEEP MEDICINE, 2009, 10 (06) :611-615
[6]   Diagnostic standards for dopaminergic augmentation of restless legs syndrome:: Report from a World Association of Sleep Medicine -: International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute [J].
Garcia-Borreguero, Diego ;
Allen, Richard P. ;
Kohnen, Ralf ;
Hoegl, Birgit ;
Trenkwalder, Claudia ;
Oertel, Wolfgang ;
Hening, Wayne A. ;
Paulus, Walter ;
Rye, David ;
Walters, Arthur ;
Winkelmann, Juliane .
SLEEP MEDICINE, 2007, 8 (05) :520-530
[7]  
GARCIABORREGUER.D, 2010, SLEEP MED REV, DOI DOI 10.1016/J.SMRV.2009.11.0006
[8]  
Hays RD., 1992, Measuring functioning and well-being: The Medical Outcomes Study approach, P232
[9]   Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study [J].
Hoegl, Birgit ;
Garcia-Borreguero, Diego ;
Kohnen, Ralf ;
Ferini-Strambi, Luigi ;
Hadjigeorgiou, Georgios ;
Hornyak, Magdolna ;
de Weerd, Al ;
Happe, Svenja ;
Stiasny-Kolster, Karin ;
Gschliesser, Viola ;
Egatz, Renata ;
Frauscher, Birgit ;
Benes, Heike ;
Trenkwalder, Claudia ;
Hening, Wayne A. ;
Allen, Richard P. .
JOURNAL OF NEUROLOGY, 2010, 257 (02) :230-237
[10]   Ropinirole is effective in the long-term management of restless legs syndrome: A randomized controlled trial [J].
Montplaisir, Jacques ;
Karrasch, Jeff ;
Haan, Jean ;
Volc, Dieter .
MOVEMENT DISORDERS, 2006, 21 (10) :1627-1635